The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Open accessAbstract
Cancer-associated IDH mutations are characterized by neomorphic enzyme activity and resultant 2-hydroxyglutarate (2HG) production. Mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specific hypermethylation signature. Furthermore, expression of 2HG-producing IDH alleles in cells induced global DNA hypermethylation. In the AML cohort, IDH1/2 mutations were mutually exclusive with mutations in the α-ketoglutarate-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar epigenetic defects as IDH1/2 mutants. Consistent with these genetic and epigenetic data, expression of IDH mutants impaired TET2 catalytic function in cells. Finally, either expression of mutant IDH1/2 or Tet2 depletion impaired hematopoietic differentiation and increased stem/progenitor cell marker expression, suggesting a shared proleukemogenic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [153]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistently, TET2-mutant immature and myeloid cells present with hypermethylation of active enhancers and perturbed TF activity (28, 32, 53).”
From PU.1-Dependent Enhancer Inhibition Separates Tet2 -Deficient Hematopoiesis from Malignant Transformation (2022) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Figueroa et al., 2010
In the citing paper
“Mutations in isocitrate dehydrogenase isoform-1 (IDH1) and IDH2 generate the oncometabolite D-2-hydroxyglutarate (D-2HG), which inhibits epigenetic enzymes including histone demethylases and the Ten-eleven translocation (TET) family of 5-methylcytosine hydroxylases.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“These effects contribute to tumor initiation in acute myelogenous leukemia (AML) by resulting in persistent histone and DNA methylation and impaired cellular differentiation (25).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [117]
In the citing paper
“In addition, TET2 inactivation is sufficient to promote hematopoietic stem cell self-renewal and to block differentiation (Figueroa et al., 2010; Li et al., 2011; Moran-Crusio et al., 2011; Noushmehr et al., 2010; Turcan et al., 2012; Losman et al., 2013).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“In this regard, TET2 and IDH mutations are both found in acute myelogenous leukemia and are mutually exclusive, consistent with the idea that R-2HG produced by mutant IDH provides an alterative means of inactivating TET2 (Figueroa et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“R-2HG, succinate, and fumarate are all capable of inhibiting multiple 2-oxoglutarate-dependent dioxygenases, including the JmjC histone demethylases and TET proteins, when present at sufficiently high concentrations (Figure 6B) (Cervera et al., 2009; Chowdhury et al., 2011; Figueroa et al., 2010; Koivunen et al., 2012; Lu et al., 2012; Smith et al., 2007; Turcan et al., 2012; Xiao et al., 2012; Xu”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“More recently, we have also learnt how the catalytic activity of EZH2 can be compromised by so called 'oncohistones' 100 (Figure 3).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“Around 30% of all paediatric glioblastomas contain mutations in histone genes resulting in H3K27M, H3K27I and H3G34V/R substitutions (reviewed in REF. 100 ).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“in a large acute myelogenous leukaemia (AML) cohort, TET2 was found to be mutually exclusive with gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 (REF.65).”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [65]
In the citing paper
“Heterozygous, inactivating ten-eleven translocation 2 (TET2) mutations and neomorphic isocitrate dehydrogenase (IDH) mutations are recurrent and mutually exclusive in acute myeloid leukaemia genomes.”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [5]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [172]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“IDH mutations in AML are mutually exclusive with inactivating mutations in TET2 methylcytosine hydroxylases, further implicating mutant IDH as a bona fide driver of epigenetic remodeling (Figueroa et al., 2010).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“Mutant IDH2 [Arg140→Gln140 (R140Q)], which promotes α-KG depletion/2-HG production, promotes DNA hypermethylation in hematopoietic cells and can inhibit myeloid differentiation when overexpressed in bone marrow stem cells (79).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“multiple groups have found that IDH mutant expression and 2HG elevation can inhibit the TET family of enzymes that hydroxylate 5’-methylcytosine (Figueroa et al., 2010; Turcan et al., 2012; Xu et al., 2011)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“TET2 mutant AML samples displayed an overlapping DNA hypermethylation signature with samples having IDH1 or IDH2 mutations”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“neomorphic mutations of IDH1 or IDH2 and TET2 loss-of-function mutations were found to be mutually exclusive in a large AML cohort”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“In both cell types, the overexpression of IDH mutants blocked acquisition of mature myeloid markers while increasing the expression of stem cell markers (Figueroa et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“shRNA knockdown of TET2 recapitulated the effect of IDH mutant overexpression on blocking hematopoietic cell differentiation (Figueroa et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“mutations in IDH1/2 and in the 5-methylcytosine hydroxylase TET2 occur frequently in acute myelogenous leukemia”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“primary IDH1- or IDH2-mutant tumors showed evidence of extensively altered histone and DNA methylation in vivo”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“the mutations were found to be mutually exclusive”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“high concentrations of 2-HG inhibited the function of α-ketoglutarate-dependent histone demethylases and 5-methylcytosine hydroxylases in vitro”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“metabolomic profiling of mIDH1/2 gliomas revealed significant alterations in cellular metabolism, an effect recapitulated with the exogenous addition of D-2-HG134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
In the citing paper
“This metabolic rewiring resulted in a decrease in a common dipeptide found in the brain N-acetyl-aspartyl-glutamate (NAAG), and NAAG levels were found to be significantly lower in IDH-mutant human glioma tissue134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationIto, S., D’Alessio, A. C., Taranova, O., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,628
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Histone demethylation by a family of JmjC domain-containing proteins
Tsukada, Y.-I., Fang, J., Erdjument‐Bromage, H., Warren, M., Borchers, C. H., Tempst, P., & Zhang, Y. (2005) · Nature · doi:10.1038/nature04433 · Cited by 2,244
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citation
Flagged first, then by citations
1 of the 35 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,005
Kraus, T. F. J., Globisch, D., Wagner, M., Eigenbrod, S., Widmann, D., Münzel, M., Müller, M., Pfaffeneder, T., Hackner, B., Feiden, W., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27429 · Cited by 146
Inborn and acquired metabolic defects in cancer
Frezza, C., Pollard, P. J., & Gottlieb, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0728-4 · Cited by 147
Emerging therapies for acute myeloid leukemia
Saygin, C., & Carraway, H. E. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0463-6 · Cited by 146
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 152
Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies
Lio, C. J., Yuita, H., & Rao, A. (2019) · Blood · doi:10.1182/blood.2019791475 · Cited by 152
Oncometabolites: tailoring our genes
Nowicki, S., & Gottlieb, E. (2015) · FEBS Journal · doi:10.1111/febs.13295 · Cited by 148
Patnaik, M. M., Hanson, C. A., Hodnefield, J. M., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.298 · Cited by 147
Gorovets, D. J., Kannan, K. S., Shen, R., Kastenhuber, E. R., Islamdoust, N., Campos, C., Pentsova, E. I., Heguy, A., Jhanwar, S. C., Mellinghoff, I. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2977 · Cited by 145
Karlstaedt, A., Zhang, X., Vitrac, H., Harmancey, R., Vasquez, H., Wang, J. H., Goodell, M. A., & Taegtmeyer, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601650113 · Cited by 144
Zhang, Y. W., Wang, Z., Xie, W., Cai, Y., Xia, L., Easwaran, H., Luo, J., Yen, R.-W. C., Li, Y., & Baylin, S. B. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.013 · Cited by 148
Self-citationKadiyala, P., Carney, S. V., Gauss, J. C., Garcia-Fabiani, M. B., Haase, S., Alghamri, M. S., Núñez, F. J., Liu, Y., Yu, M., Taher, A. W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139542 · Cited by 143
Glass, J. L., Hassane, D., Wouters, B. J., Kunimoto, H., Avellino, R., Garrett-Bakelman, F. E., Guryanova, O. A., Bowman, R., Redlich, S., Intlekofer, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1032 · Cited by 142
Self-citationCraddock, C., Quek, L. S., Goardon, N., Freeman, S. D., Siddique, S., Raghavan, M., Aztberger, A., Schuh, A., Grimwade, D. J., Ivey, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.312 · Cited by 147
Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes
Wong, B. W., Kuchnio, A., Brüning, U., & Carmeliet, P. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.10.004 · Cited by 144
IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo
Bralten, L. B. C., Kloosterhof, N. K., Balvers, R. K., Sacchetti, A., Lapre, L., Lamfers, M. L. M., Leenstra, S., de Jonge, H. R., Kros, J. M., Jansen, E. E. W., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22390 · Cited by 148
Bady, P., Delorenzi, M., & Hegi, M. E. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.009 · Cited by 144
DNA methylation aberrancies as a guide for surveillance and treatment of human cancers
Liang, G., & Weisenberger, D. J. (2017) · Epigenetics · doi:10.1080/15592294.2017.1311434 · Cited by 145
Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling
Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 143
Chromatin modifying gene mutations in follicular lymphoma
Green, M. R. (2017) · Blood · doi:10.1182/blood-2017-08-737361 · Cited by 151
Metabolic Signaling to ChromatinPreprint
Berger, S. L., & Sassone‐Corsi, P. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019463 · Cited by 145
Breathing-in epigenetic change with vitamin C
Monfort, A., & Wutz, A. (2013) · The EMBO Reports · doi:10.1038/embor.2013.29 · Cited by 140
The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
Raza, A., & Galili, N. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3321 · Cited by 150
Youssef, G., & Miller, J. J. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01040-8 · Cited by 144
Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia
Figueroa, M. E., Chen, S.-C., Andersson, A., Phillips, L. A., Li, Y., Sotzen, J. R., Kundu, M., Downing, J. R., Melnick, A. M., & Mullighan, C. G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66203 · Cited by 140
Self-citationAsmar, F., Punj, V., Christensen, J. F., Pedersen, M. T., Pedersen, A., Nielsen, A. B., Hother, C. E., Ralfkiær, U., Brown, P. D. N., Ralfkiaer, E. M., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.088740 · Cited by 147
DNA methylation as a transcriptional regulator of the immune system
Morales‐Nebreda, L., McLafferty, F. S., & Singer, B. D. (2018) · Translational research · doi:10.1016/j.trsl.2018.08.001 · Cited by 141
Critical Enzymatic Functions of FTO in Obesity and Cancer
Deng, X., Su, R. J., Stanford, S., & Chen, J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00396 · Cited by 143
Borger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2649 · Cited by 138
Fessel, J. P., Hamid, R., Wittmann, B. M., Robinson, L. J., Blackwell, T., Tada, Y., Tanabe, N., Tatsumi, K., Hemnes, A. R., & West, J. D. (2012) · Pulmonary Circulation · doi:10.4103/2045-8932.97606 · Cited by 141
Deng, G., Shen, J., Yin, M., McManus, J., Mathieu, M., Gee, P., He, T., Shi, C., Bedel, O., McLean, L. R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608497 · Cited by 138
Self-citationCancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 140
Chen, J.-Y., Li, C., Kuo, C.-C., Tsai, K. K., Hou, M., & Hung, W.-C. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0410-1 · Cited by 145
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
Patnaik, M. M., & Tefferi, A. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.5 · Cited by 137
Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic
Agrawal, K., Das, V., Vyas, P., & Hajdúch, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.006 · Cited by 141
Lachowiez, C. A., Loghavi, S., Zeng, Z., Tanaka, T. N., Kim, Y. J., Uryu, H., Turkalj, S., Jakobsen, N. A., Luskin, M. R., Duose, D. Y., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0205 · Cited by 137
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date
Bastien, J., McNeill, K. A., & Fine, H. A. (2014) · Cancer · doi:10.1002/cncr.28968 · Cited by 146
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
Chiang, S., Weigelt, B., Wen, H., Pareja, F. G., Raghavendra, A., Martelotto, L. G., Burke, K. A., Basili, T., Li, A., Geyer, F. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0298 · Cited by 137
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1
Mazor, T., Chesnelong, C., Pankov, A., Jalbert, L. E., Hong, C., Hayes, J. L., Smirnov, I. V., Marshall, R. E., de Souza, C. F., Shen, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708914114 · Cited by 139
Singh, A. M., Chappell, J., Trost, R., Lin, L., Wang, T., Tang, J., Wu, H., Zhao, S., Jin, P., & Dalton, S. (2013) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.10.009 · Cited by 136
Dufva, O., Kankainen, M., Kelkka, T., Sekiguchi, N., Awad, S. A., Eldfors, S., Yadav, B., Kuusanmäki, H. A., Malani, D., Andersson, E. I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03987-2 · Cited by 135
Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Chan, S. M., & Majeti, R. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1407-8 · Cited by 142
Metabolic alterations in cancer cells and therapeutic implications
Hammoudi, N., Ahmed, K. B. R., Garcı́a-Prieto, C., & Huang, P. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10267 · Cited by 137
Goyal, L., Govindan, A., Sheth, R. A., Nardi, V., Blaszkowsky, L. S., Faris, J. E., Clark, J. W., Ryan, D. P., Kwak, E. L., Allen, J. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0210 · Cited by 134
Mitochondria in cancer: at the crossroads of life and death
Fogg, V. C., Lanning, N. J., & MacKeigan, J. P. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10018 · Cited by 139
DNA methylation-based classification of sinonasal undifferentiated carcinoma
Doğan, S., Vasudevaraja, V., Xu, B., Serrano, J., Ptashkin, R. N., Jung, H. J., Chiang, S., Jungbluth, A. A., Cohen, M. A., Ganly, I., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0285-x · Cited by 135
Advances in epigenetic therapeutics with focus on solid tumors
Jin, N. Y., George, T. L., Otterson, G. A., Verschraegen, C. F., Wen, H., Carbone, D. P., Herman, J. G., Bertino, E. M., & He, K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01069-7 · Cited by 135
Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence?
Ficz, G., & Gribben, J. G. (2014) · Genomics · doi:10.1016/j.ygeno.2014.08.017 · Cited by 135
Molecular pathogenesis of IDH mutations in gliomas
Ichimura, K. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0090-4 · Cited by 134
Döhner, H., Dolnik, A., Tang, L., Seymour, J. F., Minden, M. D., Stone, R. M., Bernal, T., Al‐Ali, H. K., Santini, V., Vyas, P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0257-z · Cited by 132
IDH mutations in acute myeloid leukemia
Rakheja, D., Konoplev, S. N., Medeiros, L. J., & Chen, W. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.003 · Cited by 135
Balusu, R., Fiskus, W. C., Rao, R., Chong, D. G., Nalluri, S., Mudunuru, U., Ma, H., Chen, L., Venkannagari, S., Ha, K., et al. (2011) · Blood · doi:10.1182/blood-2010-09-309674 · Cited by 131
Scotland, S., Saland, E., Skuli, N., de Toni, F., Boutzen, H., Micklow, E., Sénégas, I., Peyraud, R., Peyriga, L., Théodoro, F., et al. (2013) · Leukemia · doi:10.1038/leu.2013.107 · Cited by 149
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
Stuani, L., Sabatier, M., Wang, F., Poupin, N., Bosc, C., Saland, E., Castelli, F. A., Gales, L., Montersino, C., Boët, E., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200924 · Cited by 143
Genomic insights into cancer-associated aberrant CpG island hypermethylation
Sproul, D., & Meehan, R. R. (2013) · Briefings in Functional Genomics · doi:10.1093/bfgp/els063 · Cited by 135
The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity
Vatrinet, R., Leone, G., Luise, M. D., Girolimetti, G., Vidone, M., Gasparre, G., & Porcelli, A. M. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0165-0 · Cited by 133
Global Profiling Strategies for Mapping Dysregulated Metabolic Pathways in Cancer
Benjamin, D. I., Cravatt, B. F., & Nomura, D. K. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.013 · Cited by 131
Connections Between Metabolism and Epigenetics in Programming Cellular Differentiation
Chisolm, D. A., & Weinmann, A. S. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053127 · Cited by 133
Wang, F., Morita, K., Dinardo, C. D., Furudate, K., Tanaka, T. N., Yan, Y., Patel, K. P., MacBeth, K. J., Wu, B., Liu, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22874-x · Cited by 137
Extracellular serine controls epidermal stem cell fate and tumour initiation
Baksh, S. C., Todorova, P. K., Gur-Cohen, S., Hurwitz, B., Ge, Y., Novak, J. S. S., Tierney, M. T., dela Cruz-Racelis, J., Fuchs, E., & Finley, L. W. S. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0525-9 · Cited by 128
Crosstalk between metabolism and epigenetics during macrophage polarization
Zhang, K., & Jagannath, C. (2025) · Epigenetics & Chromatin · doi:10.1186/s13072-025-00575-9 · Cited by 137
Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Al‐Khallaf, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0165-3 · Cited by 133
Peroxisomes in Immune Response and Inflammation
Cara, F. D., Andreoletti, P., Trompier, D., Véjux, A., Bülow, M. H., Sellin, J., Lizard, G., Cherkaoui‐Malki, M., & Savary, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163877 · Cited by 134
Epigenetic Aging Signatures Are Coherently Modified in Cancer
Lin, Q., & Wagner, W. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005334 · Cited by 129
Singh, A. M., Chappell, J., Trost, R., Lin, L., Wang, T., Tang, J., Matlock, B. K., Weller, K. P., Wu, H., Zhao, S., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.02.009 · Cited by 126
Translational implications of somatic genomics in acute myeloid leukaemia
Meyer, S. C., & Levine, R. L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70008-7 · Cited by 139
Self-citationNew Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
Karsy, M. J., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0722-5 · Cited by 128
Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation
Li, T., Mao, C., Wang, X., Shi, Y., & Tao, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01733-5 · Cited by 125
Böttcher, M., Renner, K., Berger, R., Mentz, K., Thomas, S., Cardenas-Conejo, Z. E., Dettmer, K., Oefner, P. J., Mackensen, A., Kreutz, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445454 · Cited by 124
Deregulation of cell signaling in cancer
Giancotti, F. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.005 · Cited by 133
Origins of aberrant DNA methylation in acute myeloid leukemia
Schoofs, T., Berdel, W. E., & Müller‐Tidow, C. (2013) · Leukemia · doi:10.1038/leu.2013.242 · Cited by 127
Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, G., Reitman, Z. J., Duncan, C. G., Spasojević, I., Gooden, D. M., Rasheed, B. A., Yang, R. R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 130
Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
Geyer, H. L., Dueck, A. C., Scherber, R. M., & Mesa, R. A. (2015) · Mediators of Inflammation · doi:10.1155/2015/284706 · Cited by 129
Current findings for recurring mutations in acute myeloid leukemia
Takahashi, S. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-36 · Cited by 128
Lai, X., Li, Q., Wu, F., Lin, J., Chen, J., Zheng, H., & Guo, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00760 · Cited by 130
Fathi, A. T., Sadrzadeh, H., Borger, D. R., Ballen, K. K., Amrein, P. C., Attar, E. C., Foster, J., Burke, M. E., Lopez, H. U., Matulis, C. R., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438267 · Cited by 125
Age-associated changes in human hematopoietic stem cells
Pang, W. W., Schrier, S. L., & Weissman, I. L. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.10.004 · Cited by 126
Prassek, V. V., Rothenberg‐Thurley, M., Sauerland, M. C., Herold, T., Janke, H., Ksienzyk, B., Konstandin, N. P., Görlich, D., Krug, U. O., Faldum, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191536 · Cited by 125
The Role of IDH Mutations in Acute Myeloid Leukemia
Bravo, G. M., & Dinardo, C. D. (2018) · Future Oncology · doi:10.2217/fon-2017-0523 · Cited by 128
de Botton, S., Montesinos, P., Schuh, A. C., Papayannidis, C., Vyas, P., Wei, A. H., Ommen, H. B., Семочкин, С. В., Kim, H., Larson, R. A., et al. (2022) · Blood · doi:10.1182/blood.2021014901 · Cited by 124
Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia
Yamazaki, J., Taby, R. F., Vasanthakumar, A., Macrae, T. A., Ostler, K. R., Shen, L., Kantarjian, H. M., Estecio, M. R., Jelı́nek, J., Godley, L. A., et al. (2012) · Epigenetics · doi:10.4161/epi.7.2.19015 · Cited by 125
Self-citationAlterations of metabolic genes and metabolites in cancer
Oermann, E. K., Wu, J., Guan, K., & Xiong, Y. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.013 · Cited by 125
Lemonnier, F., Cairns, R. A., Inoue, S., Li, W. Y., Dupuy, A., Broutin, S., Martin, N., Fataccioli, V., Pelletier, R., Wakeham, A. C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617929114 · Cited by 125
Chaturvedi, A., Herbst, L., Pusch, S., Klett, L. C., Goparaju, R., Stichel, D., Kaulfuß, S., Panknin, O., Zimmermann, K. C., Toschi, L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.46 · Cited by 125
Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
Miranda‐Gonçalves, V., Lameirinhas, A., Henrique, R., & Jerónimo, C. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00427 · Cited by 125
Ehx, G., Larouche, J., Durette, C., Laverdure, J., Hesnard, L., Vincent, K., Hardy, M., Thériault, C., Rulleau, C., Lanoix, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.001 · Cited by 129
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
Kramer, M. H., Zhang, Q., Sprung, R. W., Day, R. B., Erdmann-Gilmore, P., Li, Y., Xu, Z., Helton, N., George, D. R., Mi, Y., et al. (2022) · Blood · doi:10.1182/blood.2022016033 · Cited by 124
Self-citationMetabolic regulation of the hallmarks of stem cell biology
Jackson, B. T., & Finley, L. W. S. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.01.003 · Cited by 132
Clonal evolution of acute leukemia genomes
Jan, M., & Majeti, R. (2012) · Oncogene · doi:10.1038/onc.2012.48 · Cited by 129
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
Ohka, F., Ito, M., Ranjit, M., Senga, T., Motomura, A., Motomura, K., Saito, K., Kato, K., Kato, Y., Wakabayashi, T., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-1784-5 · Cited by 124
Janin, M., Mylonas, E., Saada, V., Micol, J., Renneville, A., Quivoron, C., Koscielny, S., Scourzic, L., Forget, S., Pautas, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.2047 · Cited by 131
DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies
Pechalrieu, D., Etiévant, C., & Arimondo, P. B. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.004 · Cited by 123
Takahashi, K., Wang, F., Morita, K., Yan, Y., Hu, P. C., Zhao, P., Zhar, A. A., Wu, C., Gumbs, C. E., Little, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04924-z · Cited by 123
Functional Assessment of Lipoyltransferase-1 Deficiency in Cells, Mice, and Humans
Ni, M., Solmonson, A., Pan, C., Yang, C., Li, D., Notzon, A., Cai, L., Guevara, G., Zacharias, L. G., Faubert, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.005 · Cited by 124
Reprogramming the epigenome with vitamin C
Lee Chong, T., Ahearn, E. L., & Cimmino, L. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00128 · Cited by 120
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H. M., Gitterman, D. P., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 122
Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms
Cross, N. C. P. (2011) · Hematology · doi:10.1182/asheducation-2011.1.208 · Cited by 125
Emerging epigenetic-modulating therapies in lymphoma
Sermer, D. J., Pasqualucci, L., Wendel, H., Melnick, A. M., & Younes, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0190-8 · Cited by 125
Self-citationvan den Bent, M. J., Erdem‐Eraslan, L., Idbaïh, A., de Rooi, J., Eilers, P. H. C., Spliet, W. G. M., den Dunnen, W. F. A., Tijssen, C. C., Wesseling, P., Smitt, P. A. E. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1157 · Cited by 120
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
Hermouet, S., Bigot‐Corbel, E., & Gardie, B. (2015) · Mediators of Inflammation · doi:10.1155/2015/145293 · Cited by 122
Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets
Mishra, S. K., Millman, S. E., & Zhang, L. (2022) · Blood · doi:10.1182/blood.2022018092 · Cited by 127
Metadata
- Authors
- Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., Tallman, M. S., Sun, Z., Wolniak, K., Peeters, J. K., Liu, W., Choe, S. E., Fantin, V. R., Paietta, E., Löwenberg, B., Licht, J. D., Godley, L. A., Delwel, R., Valk, P. J. M., Thompson, C. B., Levine, R. L., & Melnick, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Abramson Cancer Center (US)
- Weill Cornell Medicine (US)
- University of Chicago (US)
- Moffitt Cancer Center (US)
- Harvard University (US)
- Northwestern University (US)
- Erasmus MC (NL)
- Agios Pharmaceuticals (United States) (US)
- Montefiore Medical Center (US)
- Corresponding author
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- ORCID
- Abdel-Wahab, Omar
- Ward, Patrick S.
- Patel, Jay
- Shih, Alan
- Li, Yushan
- Bhagwat, Neha
- Vasanthakumar, Aparna
- Fernandez, Hugo F.
- Tallman, Martin S.
- Sun, Zhuoxin
- Wolniak, Kristy
- Liu, Wei
- Choe, Sung E.
- Fantin, Valeria R.
- Paietta, Elisabeth
- Löwenberg, Bob
- Licht, Jonathan D.
- Godley, Lucy A.
- Delwel, Ruud
- Valk, Peter J.M.
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 18
- Issue
- 6
- Pages
- 553-567
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4105845
- OpenAlex
- W2078972833
- Cited by
- 2,766
- References
- 35
- Citations by year
- 2026: 92 · 2025: 114 · 2024: 156 · 2023: 158 · 2022: 155 · 2021: 213 · 2020: 183 · 2019: 165 · 2018: 178 · 2017: 196 · 2016: 186 · 2015: 193 · 2014: 217 · 2013: 214 · 2012: 191
- FWCI
- 111.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- Agios Pharmaceuticals
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL082950)
- National Cancer Institute (CA114737, R01CA105463, U54CA143798, U24CA114737, R01CA173636, U10CA021115, CA 21115)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, IDH2 mutation, acute myeloid leukemia, DNA hypermethylation, 2-hydroxyglutarate, TET2, hematopoietic differentiation, epigenetic dysregulation, stem/progenitor cells
- MeSH terms
- MDS1 and EVI1 Complex Locus Protein, Cell Differentiation, DNA-Binding Proteins, Humans, Hydroxylation, Isocitrate Dehydrogenase, Mutation, Phenotype, Proto-Oncogene Proteins, Proto-Oncogenes, Transcription Factors, Leukemia, Myeloid, Acute, DNA Methylation, Myeloid Cells, 5-Methylcytosine, Dioxygenases, GATA1 Transcription Factor, Gene Regulatory Networks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
